J&J, Novartis second quarter sales rise

Share this article:
Johnson & Johnson reported a 13% rise in sales overall to $15.1 billion from $13.4 billion.
Major growth came from J&J's consumer business, where sales rose 49% to $3.6 billion due to the acquisition of Pfizer's consumer products business late last year.
J&J's pharmaceuticals unit posted a sales increase of 5.8% to $6.1 billion for the second quarter. Sales of J&J's antipsychotic medicines, including its top medicine Risperdal, rose 10% to $1.14 billion. Blockbuster migraine drug Topamax sold $578 million in the second quarter, up 17% from a year ago.
Novartis' sales, excluding the company's baby-food business, rose 10% to $9.4 billion from $8.5.
Novartis said it plans to use proceeds from the sale to fund targeted acquisitions and repurchase up to around $4 billion of Novartis shares by February 2008, as part of an ongoing buyback program. 
Despite second quarter sales growth, Novartis has lowered its sales outlook for the second half due to earlier than expected generic competition for hypertension drug Lotrel, the suspension of bowel drug Zelnorm in the US, and generic competition for antifungal Lamisil. 
Meanwhile, Pfizer is scheduled to release its second quarter results during a call with analysts on Wednesday.
Share this article:
You must be a registered member of MMM to post a comment.

Email Newsletters


Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...